Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Caris Life Sciences (CAI) Debt to Equity (2024 - 2025)

Caris Life Sciences has reported Debt to Equity over the past 2 years, most recently at $0.66 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.66 for Q4 2025, up 532.23% from a year ago — trailing twelve months through Dec 2025 was $0.66 (up 532.23% YoY), and the annual figure for FY2025 was $0.66, up 532.23%.
  • Debt to Equity for Q4 2025 was $0.66 at Caris Life Sciences, down from $0.79 in the prior quarter.
  • Over the last five years, Debt to Equity for CAI hit a ceiling of $0.83 in Q2 2025 and a floor of -$0.15 in Q4 2024.